BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12698985)

  • 1. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children.
    Kanamori M; Takahashi H; Echizen H
    Int J Clin Pharmacol Ther; 2002 Nov; 40(11):485-92. PubMed ID: 12698985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
    Damkier P; Brøsen K
    Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating pediatric doses of drugs metabolized by cytochrome P450 (CYP) isozymes, based on physiological liver development and serum protein levels.
    Suzuki S; Murayama Y; Sugiyama E; Hirunpanich V; Saito K; Sekiyama M; Sato H
    Yakugaku Zasshi; 2010 Apr; 130(4):613-20. PubMed ID: 20372009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
    Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
    Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
    Feierman DE; Lasker JM
    Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.
    Lytton SD; Berg U; Nemeth A; Ingelman-Sundberg M
    Clin Exp Immunol; 2002 Feb; 127(2):293-302. PubMed ID: 11876753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Björkman S
    Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
    Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
    Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats.
    Nosaka H; Nadai M; Kato M; Yasui K; Yoshizumi H; Miyoshi M; Zhao YL; Baba K; Takagi K; Hasegawa T
    Life Sci; 2006 May; 79(1):50-6. PubMed ID: 16423372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
    Damkier P; Hansen LL; Brosen K
    Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.